FDMT - צמיחת מכירות משנה לשנה ב-12 החודשים האחרונים 4D Molecular Therapeutics

4D Molecular Therapeutics is facing significant capital burn and challenges in vector manufacturing. The TTM annual sales growth rate allows for tracking revenue dynamics, where the indicator stands at 79666.30. A unique platform provides the company with patent protection and pricing power, while the development of in-house R&D in ophthalmology opens prospects for targeted technology licensing.
פילוחים אנליטיים של חברת 4D Molecular Therapeutics

This indicator measures the percentage change in revenue over twelve rolling months, allowing short-term market noise to be filtered out from actual income dynamics. An analysis of the annual sales growth rate (rolling 12 months) confirms the operational resilience of 4D Molecular Therapeutics (FDMT), demonstrating how effectively the company scales its business amidst geopolitical disruptions and shortages of consumables for global clinical trials.